journal contribution posted on 2023-04-04, 01:41 authored by Duncan R. McKenzie, Rosalind Graham, Thomas Lechmere, Clara Domingo-Vila, Thanussuyah Alaguthurai, Celeste Arman, Emily Pollock, Charalampos Gousis, Helen Kakkassery, Esme Carpenter, Ashwini Kurshan, Jennifer Vidler, Austin Kulasekararaj, Piers Patten, Bernard V. North, Timothy Tree, Katie J. Doores, Adrian C. Hayday, Sheeba Irshad
S2. T cell responses prior to SARS-CoV-2 vaccination dose 3.
Cancer Research UK (CRUK)
Leukemia and Lymphoma Society (LLS)
King's Health Partners | Guy's and St Thomas' NHS Foundation Trust
Wellcome Trust (WT)
Rosetrees Trust (Rosetrees)
ARTICLE ABSTRACTGlobal health policy reliant on SARS-CoV-2 vaccine effectiveness is underpinned by our understanding of the durability of protection offered by sequential vaccinations and the efficacy of boosting, especially in immunocompromised patient populations who might constitute virus reservoirs. Here, we have: (i) clarified in patients with cancer the degree of waning of antibodies, serum neutralization titres against parental virus and variants of concern, and T-cell responses; (ii) evaluated the immune response among patients with cancer to a third dose of COVID-19 vaccine; and (iii) provided safety data following the third dose of the BNT162b2 COVID-19 vaccine in patients with cancer.